Current Assets
Work in process
Pfizer Work in process increased by 1.4% to $5.71B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.9%, from $5.55B to $5.71B. Over 5 years (FY 2020 to FY 2025), Work in process shows an upward trend with a 4.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2015
Last reportedQ1 2026May 5, 2026
Parent metricInventories
Metric ID:
inv_work_in_progressHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.39B | $4.47B | $4.42B | $4.84B | $5.19B | $4.54B | $5.52B | $6.13B | $6.41B | $6.52B | $5.69B | $6.27B | $7.07B | $7.27B | $6.1B | $5.55B | $6.51B | $6.04B | $5.63B | $5.71B |
| QoQ Change | — | +1.8% | -1.0% | +9.5% | +7.2% | -12.6% | +21.6% | +11.1% | +4.6% | +1.7% | -12.7% | +10.3% | +12.7% | +2.8% | -16.0% | -9.0% | +17.3% | -7.3% | -6.7% | +1.4% |
| YoY Change | — | — | — | — | +18.4% | +1.6% | +24.8% | +26.6% | +23.4% | +43.5% | +3.1% | +2.3% | +10.3% | +11.5% | +7.3% | -11.5% | -7.9% | -16.9% | -7.7% | +2.9% |
| % of Inventories | 447.3% | 478.0% | 471.1% | 541.7% | 550.8% | 136.5% | 94.7% | 109.1% | 109.2% | 460.1% | 124.5% | 186.6% | 242.4% | 262.8% | 229.1% | 198.8% | 276.0% | 281.9% | 237.7% | 232.0% |
| Share Change | — | +30.7pp | -6.8pp | +70.6pp | +9.1pp | -414.3pp | -41.7pp | +14.4pp | +0.1pp | +350.9pp | -335.6pp | +62.1pp | +55.7pp | +20.5pp | -33.7pp | -30.3pp | +77.2pp | +5.9pp | -44.2pp | -5.7pp |
Range$4.39B – $7.27B
CAGR+5.7%
Avg YoY Growth+8.2%
Median YoY Growth+5.2%
Work in process at Other Companies
Frequently Asked Questions
- What is Pfizer's work in process?
- Pfizer (PFE) reported work in process of $5.71B in Q1 2026.
- How has Pfizer's work in process changed year-over-year?
- Pfizer's work in process increased by 2.9% year-over-year, from $5.55B to $5.71B.
- What is the long-term trend for Pfizer's work in process?
- Over 5 years (2020 to 2025), Pfizer's work in process has grown at a 4.9% compound annual growth rate (CAGR), from $4.43B to $5.63B.